T-1501 is a First-in-Class novel small molecule drug conjugate (SMDC) oncology drug. It uses a specific targeting agent (ZnDPA) that recognizes the specific cell surface marker (phosphatidylserine) and delivers potent anti-cancer drug (DM-1) to tumor cells.
Its activity has been demonstrated in vivo in various xenograft animal models, such as pancreatic and triple negative breast cancer. In animal studies it’s much more potent than marketed drug (kadcyla), and with less toxicity.
The preclinical study of T-1501 is in progress.